Literature DB >> 6339043

Monoclonal antibodies (F36/22 and M7/105) to human breast carcinoma.

L D Papsidero, G A Croghan, M J O'Connell, L A Valenzuela, T Nemoto, T M Chu.   

Abstract

Cloned hybridoma cell lines were obtained from fusions of murine myeloma cells with lymphocytes of mice immunized against human breast cancer cells. Hybridomas F36/22 and M7/105 produced antibodies whose binding to breast cancer cells could not be inhibited by prior absorptions with fibroblasts, lymphoblastoid cells, or erythrocytes. Results from cell surface binding assays using a panel of tumor cell lines indicated that antibodies F36/22 and M7/105 recognized determinants expressed maximally on breast cancer cells. Antibody F36/22 reacted with normal mammary epithelial membranes and milk fat globule membranes, whereas antibody M7/105 produced no detectable binding to these specimens. Antigens carrying these epitopes each showed reactivity with concanavalin A lectin. The determinant corresponding to antibody F36/22 was detectable in histological sections of a subset of breast tumors obtained at surgery.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339043

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.

Authors:  L D Papsidero; M Sheu; F W Ruscetti
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

2.  Monoclonal antibody-defined antigens of human prostate cancer cell line PC3.

Authors:  J Lindgren; M Blaszczyk; B Atkinson; Z Steplewski; H Koprowski
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer.

Authors:  M B Garcia; M A Blankenstein; E van der Wall; J W Nortier; J H Schornagel; J H Thijssen
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

4.  Purification and immunochemical characterization of ascitic fluid glycoproteins containing certain tumor-associated and blood group antigen markers.

Authors:  M Venegas; L Liu; L Lovell; L E Davis; B Anderson; T Wilbanks; M Hass; G Manderino; H Rittenhouse
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

5.  Immunohistochemical reactivity of a monoclonal antibody prepared against human breast carcinoma.

Authors:  R Mariani-Costantini; M I Colnaghi; F Leoni; S Mènard; S Cerasoli; F Rilke
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

6.  Epitope expression on the breast epithelial mucin.

Authors:  R L Ceriani; J A Peterson; E W Blank; D T Lamport
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  Reactivity of a monoclonal antibody with tissues and tumors from the human breast. Immunohistochemical localization of a new antigen and clinicopathologic correlations.

Authors:  R Mariani-Costantini; P Barbanti; M I Colnaghi; S Ménard; C Clemente; F Rilke
Journal:  Am J Pathol       Date:  1984-04       Impact factor: 4.307

8.  Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.

Authors:  P M Capone; L D Papsidero; G A Croghan; T M Chu
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

9.  Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients.

Authors:  S Iacobelli; E Arno; P Sismondi; C Natoli; N Gentiloni; G Scambia; M Giai; P Cortese; P B Panici; S Mancuso
Journal:  Breast Cancer Res Treat       Date:  1988-04       Impact factor: 4.872

10.  Immunotherapy in a spontaneously developed murine mammary carcinoma with syngeneic monoclonal antibody.

Authors:  P M Capone; N Kadohama; T M Chu
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.